Hemogenyx Pharmaceuticals Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Vladislav Sandler
Chief executive officer
UK£282.0k
Total compensation
| CEO salary percentage | 97.9% |
| CEO tenure | 10.3yrs |
| CEO ownership | 3.1% |
| Management average tenure | no data |
| Board average tenure | 6.5yrs |
Recent management updates
Recent updates
Is Hemogenyx Pharmaceuticals (LON:HEMO) In A Good Position To Deliver On Growth Plans?
Aug 21
Will Hemogenyx Pharmaceuticals (LON:HEMO) Spend Its Cash Wisely?
May 04We Think Hemogenyx Pharmaceuticals (LON:HEMO) Needs To Drive Business Growth Carefully
Jan 06Hemogenyx Pharmaceuticals (LON:HEMO) Has Debt But No Earnings; Should You Worry?
Oct 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -UK£7m |
| Sep 30 2023 | n/a | n/a | -UK£7m |
| Jun 30 2023 | n/a | n/a | -UK£7m |
| Mar 31 2023 | n/a | n/a | -UK£6m |
| Dec 31 2022 | UK£282k | UK£276k | -UK£4m |
| Sep 30 2022 | n/a | n/a | -UK£3m |
| Jun 30 2022 | n/a | n/a | -UK£3m |
| Mar 31 2022 | n/a | n/a | -UK£4m |
| Dec 31 2021 | UK£213k | UK£206k | -UK£5m |
| Sep 30 2021 | n/a | n/a | -UK£5m |
| Jun 30 2021 | n/a | n/a | -UK£5m |
| Mar 31 2021 | n/a | n/a | -UK£3m |
| Dec 31 2020 | UK£205k | UK£200k | -UK£2m |
| Sep 30 2020 | n/a | n/a | -UK£2m |
| Jun 30 2020 | n/a | n/a | -UK£2m |
| Mar 31 2020 | n/a | n/a | -UK£2m |
| Dec 31 2019 | UK£149k | UK£145k | -UK£1m |
| Sep 30 2019 | n/a | n/a | -UK£2m |
| Jun 30 2019 | n/a | n/a | -UK£2m |
| Mar 31 2019 | n/a | n/a | -UK£2m |
| Dec 31 2018 | UK£98k | UK£94k | -UK£2m |
| Sep 30 2018 | n/a | n/a | -UK£2m |
| Jun 30 2018 | n/a | n/a | -UK£3m |
| Mar 31 2018 | n/a | n/a | -UK£3m |
| Dec 31 2017 | UK£79k | UK£79k | -UK£2m |
Compensation vs Market: Vladislav's total compensation ($USD354.23K) is about average for companies of similar size in the UK market ($USD346.19K).
Compensation vs Earnings: Vladislav's compensation has increased whilst the company is unprofitable.
CEO
Vladislav Sandler (58 yo)
10.3yrs
Tenure
UK£282,000
Compensation
Dr. Vladislav Sandler, Ph D., is a Co-Founder of Hemogenyx Pharmaceuticals Plc. and serves as its Chief Executive Officer since December 2013 and serves as its Director.Dr. Sandler also serves as Chief Ex...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 6.5yrs | UK£282.00k | 3.1% £ 643.1k | |
| Independent Co-Founder & Non-Executive Director | 6.5yrs | UK£57.00k | 5.6% £ 1.2m | |
| Clinical Advisor & Medical Director | no data | no data | no data | |
| Member of Scientific Advisory Board | 6.1yrs | no data | no data | |
| Independent Non-Executive Director | 8.8yrs | UK£50.00k | 0.42% £ 86.6k | |
| Board Observer & Business Advisor | 2.8yrs | no data | no data | |
| Independent Chairman & Chairman of Advisory Board | 6.6yrs | UK£15.00k | no data | |
| Scientific Advisor | no data | no data | no data |
6.5yrs
Average Tenure
67yo
Average Age
Experienced Board: HEMO's board of directors are considered experienced (6.5 years average tenure).